Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Mauri

Showing results (211-220 of 335) with videos related to

Pageof 34
Sort By:
American Heart Journal|December 15, 2010
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesionsLaura Mauri, Dean J Kereiakes, Sharon-Lise T Normand, et al.
Circulation|November 18, 2014
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placementKirk N Garratt, W Douglas Weaver, Ronald G Jenkins, et al.
The New England Journal of Medicine|March 13, 2013
Nonemergency PCI at hospitals with or without on-site cardiac surgeryAlice K Jacobs, Sharon-Lise T Normand, Joseph M Massaro, et al.
American Heart Journal|March 20, 2012
Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trialOluseun O Alli, Paul S Teirstein, Lowell Satler, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 4, 2010
Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II studyJean Fajadet, William Wijns, Gert-Jan Laarman, et al.
JACC. Cardiovascular Interventions|August 22, 2009
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registryVictor Novack, Donald Cutlip, Neal Kleiman, et al.
Circulation. Cardiovascular Interventions|October 26, 2018
Benefit and Risk of Prolonged DAPT After Coronary Stenting in WomenNatalia C Berry, Dean J Kereiakes, Robert W Yeh, et al.
Journal of the American Heart Association|May 28, 2013
Risk-treatment paradox in the selection of transradial access for percutaneous coronary interventionNeil J Wimmer, Frederic S Resnic, Laura Mauri, et al.
Glycoconjugate Journal|March 22, 2020
Gangliosides in the differentiation process of primary neurons: the specific role of GM1-oligosaccharideErika Di Biase, Giulia Lunghi, Maria Fazzari, et al.
Lancet (London, England)|August 31, 2017
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trialDavid E Kandzari, Laura Mauri, Jacques J Koolen, et al.
Pageof 34

Showing results (211-220 of 335) with videos related to

Sort By:
Pageof 34
American Heart Journal|December 15, 2010
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesionsLaura Mauri, Dean J Kereiakes, Sharon-Lise T Normand, et al.
Circulation|November 18, 2014
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placementKirk N Garratt, W Douglas Weaver, Ronald G Jenkins, et al.
The New England Journal of Medicine|March 13, 2013
Nonemergency PCI at hospitals with or without on-site cardiac surgeryAlice K Jacobs, Sharon-Lise T Normand, Joseph M Massaro, et al.
American Heart Journal|March 20, 2012
Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trialOluseun O Alli, Paul S Teirstein, Lowell Satler, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 4, 2010
Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II studyJean Fajadet, William Wijns, Gert-Jan Laarman, et al.
JACC. Cardiovascular Interventions|August 22, 2009
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registryVictor Novack, Donald Cutlip, Neal Kleiman, et al.
Circulation. Cardiovascular Interventions|October 26, 2018
Benefit and Risk of Prolonged DAPT After Coronary Stenting in WomenNatalia C Berry, Dean J Kereiakes, Robert W Yeh, et al.
Journal of the American Heart Association|May 28, 2013
Risk-treatment paradox in the selection of transradial access for percutaneous coronary interventionNeil J Wimmer, Frederic S Resnic, Laura Mauri, et al.
Glycoconjugate Journal|March 22, 2020
Gangliosides in the differentiation process of primary neurons: the specific role of GM1-oligosaccharideErika Di Biase, Giulia Lunghi, Maria Fazzari, et al.
Lancet (London, England)|August 31, 2017
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trialDavid E Kandzari, Laura Mauri, Jacques J Koolen, et al.
Pageof 34